Zevra Therapeutics Inc (ZVRA)
4.73
-0.03
(-0.63%)
USD |
NASDAQ |
May 17, 16:00
4.73
0.00 (0.00%)
After-Hours: 20:00
Zevra Therapeutics Enterprise Value: 188.25M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 188.25M |
| May 16, 2024 | 189.50M |
| May 15, 2024 | 192.01M |
| May 14, 2024 | 191.18M |
| May 13, 2024 | 194.94M |
| May 10, 2024 | 192.01M |
| May 09, 2024 | 200.80M |
| May 08, 2024 | 206.25M |
| May 07, 2024 | 206.87M |
| May 06, 2024 | 206.04M |
| May 03, 2024 | 191.60M |
| May 02, 2024 | 189.07M |
| May 01, 2024 | 182.79M |
| April 30, 2024 | 181.96M |
| April 29, 2024 | 180.70M |
| April 26, 2024 | 179.45M |
| April 25, 2024 | 179.45M |
| April 24, 2024 | 181.12M |
| April 23, 2024 | 181.96M |
| April 22, 2024 | 181.54M |
| April 19, 2024 | 179.45M |
| April 18, 2024 | 178.61M |
| April 17, 2024 | 184.47M |
| April 16, 2024 | 189.91M |
| April 15, 2024 | 190.54M |
| Date | Value |
|---|---|
| April 12, 2024 | 191.16M |
| April 11, 2024 | 197.02M |
| April 10, 2024 | 196.19M |
| April 09, 2024 | 188.23M |
| April 08, 2024 | 197.02M |
| April 05, 2024 | 192.00M |
| April 04, 2024 | 195.77M |
| April 03, 2024 | 200.79M |
| April 02, 2024 | 204.35M |
| April 01, 2024 | 206.23M |
| March 31, 2024 | 233.01M |
| March 28, 2024 | 217.76M |
| March 27, 2024 | 223.62M |
| March 26, 2024 | 214.41M |
| March 25, 2024 | 211.07M |
| March 22, 2024 | 216.09M |
| March 21, 2024 | 217.59M |
| March 20, 2024 | 225.90M |
| March 19, 2024 | 222.16M |
| March 18, 2024 | 222.58M |
| March 15, 2024 | 224.24M |
| March 14, 2024 | 230.47M |
| March 13, 2024 | 235.87M |
| March 12, 2024 | 234.21M |
| March 11, 2024 | 229.64M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
36.80M
Minimum
May 11 2022
409.55M
Maximum
Jun 23 2021
134.96M
Average
114.82M
Median
Jun 13 2023
Enterprise Value Benchmarks
| Perspective Therapeutics Inc | 817.27M |
| Dare Bioscience Inc | 45.43M |
| OptiNose Inc | 221.44M |
| Kodiak Sciences Inc | -72.55M |
| INmune Bio Inc | 196.09M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.62M |
| Revenue (Quarterly) | 3.425M |
| Total Expenses (Quarterly) | 23.91M |
| EPS Diluted (Quarterly) | -0.40 |
| Gross Profit Margin (Quarterly) | 50.28% |
| Profit Margin (Quarterly) | -485.3% |
| Earnings Yield | -28.54% |
| Normalized Earnings Yield | -30.53 |